Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × Medroxyprogesterone Acetate × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Endometrial Neoplasms 9 Polycystic Ovary Syndrome 3 Infertility 2 Endometrial Hyperplasia 2 Anovulation 2 Vitamin D Deficiency 1 Turcot syndrome 1 Neoplasms 1 Menorrhagia 1 Leiomyoma 1 Endometrial Adenocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Endometrioid 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 146 Gemcitabine 134 Paclitaxel 126 Carboplatin 116 Bevacizumab 108 Docetaxel 94 Cyclophosphamide 93 Cisplatin 92 Exercise 78 Nivolumab 77 Fluorouracil 73 Capecitabine 72 Dexamethasone 70 Irinotecan 62 Radiotherapy 57 Pemetrexed 57 Oxaliplatin 57 Standard of Care 55 Leucovorin 53 Cetuximab 47 Drug Therapy 45 Sorafenib 44 Erlotinib Hydrochloride 44 Doxorubicin 41 atezolizumab 40 Blood Specimen Collection 40 130-nm albumin-bound paclitaxel 37 trametinib 34 Ipilimumab 34 venetoclax 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06979596 2026-03-06

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡